Site Image

Study Overview

The Randomized Elimination or ProLongation of Angiotensin Converting Enzyme inhibitors and angiotensin receptor blockers in Coronavirus Disease 2019

This trial is open to hospitalized patients only.

Doctors have noticed that patients with high blood pressure, diabetes, or heart disease have a higher risk of death from COVID-19. We want to better understand why this happens and how to treat it so we can help patients with COVID-19 get better. 

The purpose of the study is to compare the effect of stopping versus continuing ACEI or ARBs in patients who have COVID-19. 

Study Description

You have been invited to participate in this research study because the treating team suspects you have developed COVID-19, or you have tested positive for it, and you regularly take either an ACEI or ARB as part of your clinical care. ACEI and ARBs may impact how COVID-19 affects the body, but we do not know if these medications help or hurt the virus. These medications may enhance binding of the virus to cells in the body (which would be harmful), but they may also enhance the protective response of the body to the virus (which would be helpful). Since we don’t know whether these can ben benefitial or harmful, our goal is to look at the effect of temporarily stopping these medications while someone is hospitalized for COVID-19.

  • Study Identifier: 842810

Recruitment Status

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email